Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

Related Articles by Review for PubMed (Select 21968126)

1.

Estimating treatment effects for individual patients based on the results of randomised clinical trials.

Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR.

BMJ. 2011 Oct 3;343:d5888. doi: 10.1136/bmj.d5888.

3.
4.

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

Kones R.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Review.

PMID:
19460829
5.
6.
7.

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

O'Keefe JH, Carter MD, Lavie CJ, Bell DS.

Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Review.

PMID:
19491548
8.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
9.

Efficacy and safety of rosuvastatin in the management of dyslipidemia.

Rubba P, Marotta G, Gentile M.

Vasc Health Risk Manag. 2009;5(1):343-52. Epub 2009 Apr 8. Review.

10.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
11.

Moving toward new statin guidelines in a post-JUPITER world: principles to consider.

Ridker PM.

Curr Atheroscler Rep. 2009 Jul;11(4):249-56. Review.

PMID:
19500487
12.

The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.

Narla V, Blaha MJ, Blumenthal RS, Michos ED.

Vasc Health Risk Manag. 2009;5:1033-42. Epub 2009 Dec 29. Review.

13.

Should we measure C-reactive protein on earth or just on JUPITER?

Bajpai A, Goyal A, Sperling L.

Clin Cardiol. 2010 Apr;33(4):190-8. doi: 10.1002/clc.20681. Review.

PMID:
20394038
15.

[Statins in primary prophylaxis of cardiovascular diseases].

Kobalava ZhD, Villeval'de SV.

Ter Arkh. 2011;83(9):70-5. Review. Russian.

PMID:
22145392
16.

Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M.

Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Review.

PMID:
20585068
17.

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.

Long SB, Blaha MJ, Blumenthal RS, Michos ED.

Clin Interv Aging. 2011;6:27-35. doi: 10.2147/CIA.S8101. Epub 2010 Dec 22. Review.

18.

Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?

Efthimiadis A.

Angiology. 2008 Apr-May;59(2 Suppl):62S-4S. doi: 10.1177/0003319708321668. Epub 2008 Jul 15. Review.

PMID:
18628276
19.

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK.

Int J Clin Pract. 2009 Mar;63(3):478-85. doi: 10.1111/j.1742-1241.2008.01979.x. Review.

PMID:
19222633
20.

[From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].

Márk L, Katona A.

Orv Hetil. 2009 Nov 1;150(44):2012-8. doi: 10.1556/OH.2009.28740. Review. Hungarian.

PMID:
19861287
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk